BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• Pharm Country

  STRATA Skin Sciences to Present at Upcoming October Conferences

  STRATA Skin Sciences, Inc. today announced that the company will be presenting at several conferences during October.

  September 27, 2023

   · 

  3 min read
• Deals

  HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

  Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock.

  September 27, 2023

   · 

  5 min read
• Business

  Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution)

  Viatris Inc. and Ocuphire Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI™.

  September 27, 2023

   · 

  10 min read
• Biotech Bay

  Totus Medicines CEO to Chair Next-Generation Undruggable and Present at Future of R&D Week 2023

  Totus Medicines today announced its participation at this year’s Future of R&D Week in Boston from October 3-5.

  September 27, 2023

   · 

  2 min read
• Pharm Country

  NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff

  NanoVibronix, Inc. today announced that its application for UroShield actuators to be available on NHS Prescription Services’ Drug Tariff has been approved.

  September 27, 2023

   · 

  6 min read
• Biotech Beach

  Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

  Adcentrx Therapeutics today announced the first patient dosed in the Phase 1a/b study of ADRX-0706 for the treatment of advanced solid tumors.

  September 27, 2023

   · 

  2 min read
• Biotech Beach

  Kurin, Inc. Named 2023 Diverse Supplier of the Year by Vizient

  Kurin, Inc. has been named the 2023 Diverse Supplier of the Year by Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company.

  September 27, 2023

   · 

  2 min read
• Business

  Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease

  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered an agreement with Roche for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer’s disease (AD) and Huntington’s disease (HD).

  September 27, 2023

   · 

  6 min read
• Policy

  BrainStorm Cell Therapeutics Stock Trading Halted Today

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that Nasdaq has halted trading of the Company’s common stock.

  September 27, 2023

   · 

  7 min read
• Drug Development

  Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes

  Kallyope, Inc. today announced the initiation of their Phase 2 trial evaluating K-757 and K-833.

  September 27, 2023

   · 

  4 min read